Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris Tokyo, September 21, 2019: …
Tokyo September 21, 2019: Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being…
New Delhi, September 19, 2019: Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of…
Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings Tokyo, August 29, 2019: Eisai Co., Ltd. will launch ETAK(…
Tokyo, August 29, 2019: Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of…
New Delhi, July 25, 2019: Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving…
For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…
Without Significant Effects on Synaptic Function in Brain by Spinal Densitiy Evaluation at Effective Dose to Decrease Amyloid Beta Level…
Tokyo, July 18, 2019: Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma…
Tokyo, May 16, 2019: Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its…